Reuters logo
BRIEF-Beigene announces first patient dosing in China phase I trial with investigational anti-pd-1 monoclonal antibody bgb-a317
December 30, 2016 / 2:34 PM / 9 months ago

BRIEF-Beigene announces first patient dosing in China phase I trial with investigational anti-pd-1 monoclonal antibody bgb-a317

Dec 30 (Reuters) - Beigene Ltd

* Beigene ltd- dosing of first patient in phase i clinical trial of bgb-a317 in mainland chinese patients with advanced solid tumors

* Beigene announces first patient dosing in china phase i trial with investigational anti-pd-1 monoclonal antibody bgb-a317 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below